29 July 2013 - Deborah Wilkes
Archived
Perrigo is poised to acquire Elan – the Irish biotechnology company behind the multiple sclerosis drug Tysabri (natalizumab) – in a cash and stock deal worth US$8.6 billion.
New to OTCToolbox?
This is available as part of an Annual Subscription to the OTCToolbox website.